Skip Nav Destination
Advancing drug development in myelodysplastic syndromes
Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis
